1. Home
  2. RBOT vs BCDA Comparison

RBOT vs BCDA Comparison

Compare RBOT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vicarious Surgical Inc.

RBOT

Vicarious Surgical Inc.

HOLD

Current Price

$2.76

Market Cap

17.9M

Sector

Health Care

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.35

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBOT
BCDA
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RBOT
BCDA
Price
$2.76
$1.35
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$25.00
AVG Volume (30 Days)
156.2K
97.6K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$1.00
52 Week High
$16.92
$3.20

Technical Indicators

Market Signals
Indicator
RBOT
BCDA
Relative Strength Index (RSI) 52.34 58.07
Support Level $2.40 $1.26
Resistance Level $2.86 $1.32
Average True Range (ATR) 0.26 0.07
MACD 0.13 0.01
Stochastic Oscillator 83.33 88.00

Price Performance

Historical Comparison
RBOT
BCDA

About RBOT Vicarious Surgical Inc.

Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: